Subscribe - argenx

Argenx uses cookies on this site to enhance your user experience. More information

I agree

Events
Contact

Home
About us
Products
Partnering
Investors
News & Events

Events
Contact

Home
About us
Products
- Overview
- Autoimmunity
  - Efgartigimod
  - ARGX-117
- Oncology
- Discovery programs
- Technology
Partnering
Investors
News & Events

argenx to present at JP Morgan HC, Jan 10 2019 - 10 AM PT, San Francisco: Presentation and Q&A

Home
News & Events
Subscribe

Subscribe

Subscribe to our news service and stay up-to-date

Title * MrMrsDr
First name *	Family name *
Email adress *
Language * FrenchEnglishDutch
Profile * Sell-side (Analyst, Equity Sales)Buy-side (Analyst, Institutional Investor) ShareholderPrivate investor Pharmaceutical ExecutiveLocal Press International PressOther
I wish to receive press releases I wish to receive financial reports
Send

Company news

argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology

February 04, 2019

argenx announces closing of exclusive global collaboration and license agreement for cusatuzumab (ARGX-110) with Janssen

January 18, 2019

Contact

argenx SE
Breda, The Netherlands
T +31 763 030 488

info@argenx.com

argenx BVBA
Zwijnaarde, Belgium
T +32 9 310 34 00

argenx US Inc.
Boston, MA

Downloads

JP Morgan HC 2019, Corporate Presentation Workshop ITP Ph2 & AML Ph1/2 clincial data Corporate presentation Nov 2018

Follow us

2019 © argenx

| Disclaimer | Cookie policy | Sitemap

Home
About us
Products
Partnering
Investors
News & Events

Created by Cantilis